ClinicalTrials.gg
CompletedNCT00335725Updated Mar 27, 2015Results posted

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

A Phase 3 interventional study of Follicle Stimulating Hormone and Follicle Stimulating Hormone in Infertility, sponsored by IBSA Institut Biochimique SA. Completed at 7 sites in 2 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2015-03-27.

Sponsored by IBSA Institut Biochimique SA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Follicle Stimulating Hormone in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Follicle Stimulating Hormone · Infertility.

Enrollment
9th of 12
151 · median 239
Started
2003
the only one that year
Phase 3
6 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
1 of 12
IBSA Institut Biochimique SA

Among the 12 studies testing Follicle Stimulating Hormone in Infertility, this one is the 9th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 3, and was the 1st registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 12 studies testing Follicle Stimulating Hormone in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Follicle Stimulating Hormone

Follicle Stimulating Hormone: first FDA approval 1997 (GONAL-F). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Follicle Stimulating Hormone in Infertility, or all of them as a file.
02

Study summary

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Serono) when administered in patients undergoing ICSI

Read the detailed description

This is a multicentric, prospective, randomised, investigator blind, controlled clinical trial (phase III) of two parallel groups, one receiving the test drug FSH (Fostimon® , IBSA) and the other the reference drug FSH (Gonal-F®, Serono). The groups will be paired on the major prognostic criteria.

In effect, a double blind trial is not really feasible since the drugs presentations are very different. However, in IVF, drugs are usually dispensed and/or injected by a nurse and therefor the Investigator can be blind. Moreover, the used preparations will contain the same amount of gonadotrophin units (75 IU), will be repackaged in anonymous boxes and the following sentence will be written in the Patient Information Sheet: "You are required not to inform the Investigator about the product's name".

The randomisation is necessary to get groups as comparable as possible for all the other aspects. The multicentric design has the double interest of facilitating the patients' recruitment and of decreasing the biases related to attitudes in a specific centre.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Ovarian stimulation
  • Infertility
  • ICSI
  • FSH
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Women undergoing ovarian stimulation for IntraCytoplasmic Sperm Injection (ICSI) with the following characteristics:

>/= 18 and \< 40 years old between 19 and 30 kg/m2 less than 3 previous completed cycles basal FSH level less than 10 IU/l within the 6 months prior to the study

Exclusion criteria

Exclusion Criteria:

age \< 18 and >/= 40 years primary ovarian failure or women known as poor responders, i.e. requiring more than 225 IU of FSH as starting dose in previous treatment cycles or having less than 3 oocytes retrieved or with an oestradiol serum concentration \< 900 pmol/l (250 pg/ml) ovarian cysts > 20 mm oocyte donation thawed embryos replacement patients affected by pathologies associated with any of being pregnant ascertained or presumptive to the active principle and/or their ingredients abnormal bleeding of undetermined origin uncontrolled thyroid or adrenal dysfunction neoplasias severe impairment of the renal and/or hepatic functions women deprived of their freedom by administrative or legal decision

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Fostimon

    Fostimon is an highly purified FSH preparation.

    Drug: Follicle Stimulating Hormone

  • Active comparator
    Gonal-F

    Gonal-F is a recombinant FSH preparation.

    Drug: Follicle Stimulating Hormone

Interventions

06

What researchers measure

Primary outcomes

  1. Total Number of Oocytes Retrieved

    Total number of oocytes retrieved

    Time frame: 10 days after stimulation start

Secondary outcomes

  1. Clinical Pregnancy Rate

    clinical pregnancy rate defined as the presence of gestation sac and heart beat.

    Time frame: 6 weeks after treatment start

07

Results

Posted Mar 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneFostimonGonal-f
Started7576
Completed7171
Not completed45

Outcome measures

PrimaryTotal Number of Oocytes Retrieved

Total number of oocytes retrieved

Time frame:
10 days after stimulation start
Reported as:
Mean · oocytes
Total Number of Oocytes Retrieved
oocytesFostimonGonal-f
Total Number of Oocytes Retrieved10.9 ± 4.912.0 ± 5.6
SecondaryClinical Pregnancy Rate

clinical pregnancy rate defined as the presence of gestation sac and heart beat.

Time frame:
6 weeks after treatment start
Reported as:
Number · percentage of treated patients
Clinical Pregnancy Rate
percentage of treated patientsFostimonGonal-F
Clinical Pregnancy Rate30.129.2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fostimon—2/73 (2.7%)3/73 (4.1%)
Gonal-F—5/72 (6.9%)3/72 (4.2%)
Most frequent serious events
Most frequent serious events
EventFostimonGonal-F
OHSSPregnancy, puerperium and perinatal conditions1/734/72
Spontaneous abortionPregnancy, puerperium and perinatal conditions0/731/72
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/730/72
Most frequent other events
Most frequent other events
EventFostimonGonal-F
Ovarian cystPregnancy, puerperium and perinatal conditions2/731/72
spontaneous abortionPregnancy, puerperium and perinatal conditions1/731/72
tirednessGeneral disorders0/731/72

Baseline characteristics

Age, Continuous
Age, Continuous(years)FostimonGonal-fTotal
Mean29.9 ± 4.030.0 ± 3.630.0 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)FostimonGonal-fTotal
Female7576151
Male000
basal FSH
basal FSH(IU/L)FostimonGonal-fTotal
Mean5.9 ± 2.56.0 ± 1.96.0 ± 2.2
08

Study locations

7 sites
  • Private Consulting
    Bron, France
  • Hôpital Jeanne de Flandre
    Lille, France
  • Hôpital Edouard Herriot
    Lyon, France
  • Institut de Médecine de la Reproduction
    Marseille, France
  • Hôpital Américain
    Neuilly sur Seine, France
  • Hôpital Tenon
    Paris, France
  • Semmelweis Medical School
    Budapest, Hungary
09

References and documents

Publications

  • GEMZELL CA, DICZFALUSY E, TILLINGER G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). J Clin Endocrinol Metab. 1958 Dec;18(12):1333-48. doi: 10.1210/jcem-18-12-1333. No abstract available. PubMed 13611018 ↗
  • Thompson CR, Hansen LM. Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy. Fertil Steril. 1970 Dec;21(12):844-53. doi: 10.1016/s0015-0282(16)37925-0. No abstract available. PubMed 5481991 ↗
  • Oelsner G, Serr DM, Mashiach S, Blankstein J, Snyder M, Lunenfeld B. The study of induction of ovulation with menotropins: analysis of results of 1897 treatment cycles. Fertil Steril. 1978 Nov;30(5):538-44. doi: 10.1016/s0015-0282(16)43634-4. No abstract available. PubMed 720642 ↗
  • Schwartz M, Jewelewicz R, Dyrenfurth I, Tropper P, Vande Wiele RL. The use of human menopausal and chorionic gonadotropins for induction of ovulation. Sixteen years' experience at the Sloane Hospital for Women. Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):801-7. doi: 10.1016/s0002-9378(16)32740-5. PubMed 6778212 ↗
  • Notation AD, Tagatz GE, Steffes MW. Serum 17beta-estradiol. Index of follicular maturation during gonadotropin therapy. Obstet Gynecol. 1978 Feb;51(2):204-9. PubMed 622235 ↗
  • Dore PC, Rice C, Killick S. Human gonadotrophin preparations. May cause allergic reaction. BMJ. 1994 Jun 4;308(6942):1509. doi: 10.1136/bmj.308.6942.1509b. No abstract available. PubMed 8019294 ↗
  • Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod. 1994 Mar;9(3):424-30. doi: 10.1093/oxfordjournals.humrep.a138522. PubMed 8006130 ↗
  • Wikland M, Borg J, Hamberger L, Svalander P. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod. 1994 Aug;9(8):1430-6. doi: 10.1093/oxfordjournals.humrep.a138724. PubMed 7989500 ↗
  • Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod. 1999 Sep;14(9):2207-15. doi: 10.1093/humrep/14.9.2207. PubMed 10469682 ↗
  • Remorgida V, Venturini PL, Anserini P, Lanera P, De Cecco L. Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: hormonal evaluations and clinical perspectives. Am J Obstet Gynecol. 1989 Jan;160(1):108-13. doi: 10.1016/0002-9378(89)90099-9. PubMed 2492145 ↗
  • Hackeloer BJ, Fleming R, Robinson HP, Adam AH, Coutts JR. Correlation of ultrasonic and endocrinologic assessment of human follicular development. Am J Obstet Gynecol. 1979 Sep 1;135(1):122-8. PubMed 474642 ↗
  • Venturoli S, Paradisi R, Fabbri R, Magrini O, Porcu E, Flamigni C. Comparison between human urinary follicle-stimulating hormone and human menopausal gonadotropin treatment in polycystic ovary. Obstet Gynecol. 1984 Jan;63(1):6-11. PubMed 6419189 ↗
  • Mendelson EB, Bohm-Velez M, Joseph N, Neiman HL. Gynecologic imaging: comparison of transabdominal and transvaginal sonography. Radiology. 1988 Feb;166(2):321-4. doi: 10.1148/radiology.166.2.3275976. PubMed 3275976 ↗
  • Fleischer AC. Transabdominal and transvaginal sonography of ovarian masses. Clin Obstet Gynecol. 1991 Jun;34(2):433-42. doi: 10.1097/00003081-199106000-00027. PubMed 1868645 ↗
  • Wang CF, Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil Steril. 1980 May;33(5):479-86. doi: 10.1016/s0015-0282(16)44711-4. PubMed 6768596 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 9 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2006
First posted
Jun 12, 2006
Start
Mar 2003
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Results first posted
Mar 27, 2015
Last update
Mar 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00335725
First posted
Jun 12, 2006
Start date
Mar 2003
Primary completion
Dec 2005
Completion
Dec 2005
Results posted
Mar 27, 2015
Last update
Mar 27, 2015

Study contacts

J G Grudzinskas, Prof
principal investigator · The Bridge Centre One St Thomas Street London Bridge London SE1 9RY, UK2.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follicle Stimulating Hormone

Start the discussion